The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Individual NSAIDs and Upper Gastrointestinal Complications: A Systematic Review and Meta-Analysis of Observational Studies (the SOS Project)
Open accessAbstract
BACKGROUND: The risk of upper gastrointestinal (GI) complications associated with the use of NSAIDs is a serious public health concern. The risk varies between individual NSAIDs; however, there is little information on the risk associated with some NSAIDs and on the impact of risk factors. These data are necessary to evaluate the benefit-risk of individual NSAIDs for clinical and health policy decision making. Within the European Community's Seventh Framework Programme, the Safety Of non-Steroidal anti-inflammatory drugs (NSAIDs) [SOS] project aims to develop decision models for regulatory and clinical use of individual NSAIDs according to their GI and cardiovascular safety. OBJECTIVE: The aim of this study was to conduct a systematic review and meta-analysis of observational studies to provide summary relative risks (RR) of upper GI complications (UGIC) associated with the use of individual NSAIDs, including selective cyclooxygenase-2 inhibitors. METHODS: We used the MEDLINE database to identify cohort and case-control studies published between 1 January 1980 and 31 May 2011, providing adjusted effect estimates for UGIC comparing individual NSAIDs with non-use of NSAIDs. We estimated pooled RR and 95% CIs of UGIC for individual NSAIDs overall and by dose using fixed- and random-effects methods. Subgroup analyses were conducted to evaluate methodological and clinical heterogeneity between studies. RESULTS: A total of 2984 articles were identified and 59 were selected for data abstraction. After review of the abstracted information, 28 studies met the meta-analysis inclusion criteria. Pooled RR ranged from 1.43 (95% CI 0.65, 3.15) for aceclofenac to 18.45 (95% CI 10.99, 30.97) for azapropazone. RR was less than 2 for aceclofenac, celecoxib (RR 1.45; 95% CI 1.17, 1.81) and ibuprofen (RR 1.84; 95% CI 1.54, 2.20); 2 to less than 4 for rofecoxib (RR 2.32; 95% CI 1.89, 2.86), sulindac (RR 2.89; 95% CI 1.90, 4.42), diclofenac (RR 3.34; 95% CI 2.79, 3.99), meloxicam (RR 3.47; 95% CI 2.19, 5.50), nimesulide (RR 3.83; 95% CI 3.20, 4.60) and ketoprofen (RR 3.92; 95% CI 2.70, 5.69); 4-5 for tenoxicam (RR 4.10; 95% CI 2.16, 7.79), naproxen (RR 4.10; 95% CI 3.22, 5.23), indometacin (RR 4.14; 95% CI 2.91, 5.90) and diflunisal (RR 4.37; 95% CI 1.07, 17.81); and greater than 5 for piroxicam (RR 7.43; 95% CI 5.19, 10.63), ketorolac (RR 11.50; 95% CI 5.56, 23.78) and azapropazone. RRs for the use of high daily doses of NSAIDs versus non-use were 2-3 times higher than those associated with low daily doses. CONCLUSIONS: We confirmed variability in the risk of UGIC among individual NSAIDs as used in clinical practice. Factors influencing findings across studies (e.g. definition and validation of UGIC, exposure assessment, analysis of new vs prevalent users) and the scarce data on the effect of dose and duration of use of NSAIDs and on concurrent use of other medications need to be addressed in future studies, including SOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
(2014) · Medical Entomology and Zoology · Cited by 17,633
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,154
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
García Rodríguez, L., & Jick, H. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91843-0 · Cited by 975
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
Langman, M. J. S., Weil, J., Wainwright, P., Lawson, D. H., Rawlins, M. D., Logan, R. F. A., Murphy, M., Vessey, M. P., & Colin-Jones, D. G. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90185-6 · Cited by 872
Griffin, M. R., Piper, J. M., Daugherty, J. R., Snowden, M., & Ray, W. A. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-4-257 · Cited by 758
Hernández-Díaz, S., & Rodríguez, L. A. G. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2093 · Cited by 716
Cited by
Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage
Sostres, C., Gargallo, C. J., & Lanas, A. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4175 · Cited by 406
Non-steroidal anti-inflammatory drugs for chronic low back pain
Enthoven, W. T., Roelofs, P. D., Deyo, R. A., van Tulder, M. W., & Koes, B. W. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012087 · Cited by 399
The influence of non-steroidal anti-inflammatory drugs on the gut microbiome
Rogers, M. A. M., & Aronoff, D. M. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.10.003 · Cited by 346
Theken, K. N., Lee, C. R., Gong, L., Caudle, K. E., Formea, C. M., Gaedigk, A., Klein, T. E., Agúndez, J. A. G., & Grosser, T. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1830 · Cited by 351
Acute pain: a multifaceted challenge – the role of nimesulide
Kress, H. G., Baltov, A., Basiński, A., Berghea, F., Castellsague, J., Codreanu, C., Copaciu, E., Giamberardino, M. A., Hakl, M., Hrazdira, L., et al. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1100986 · Cited by 316
Self-citationBruyère, O., Cooper, C., Pelletier, J.-P., Maheu, E., Rannou, F., Branco, J., Luisa Brandi, M., Kanis, J. A., Altman, R. D., Hochberg, M. C., et al. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2015.11.010 · Cited by 274
Management of Osteoarthritis: Expert Opinion on NSAIDs
Magni, A., Agostoni, P., Bonezzi, C., Massazza, G., Menè, P., Savarino, V., & Fornasari, D. (2021) · Pain and Therapy · doi:10.1007/s40122-021-00260-1 · Cited by 201
Schmidt, M., Lamberts, M., Olsen, A.-M. S., Fosbøll, E., Niessner, A., Tamargo, J., Rosano, G., Agewall, S., Kaski, J. C., Kjeldsen, K., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv505 · Cited by 164
Gwee, K.-A., Goh, V., Lima, G., & Setia, S. (2018) · Journal of Pain Research · doi:10.2147/jpr.s156938 · Cited by 117
Haghbin, H., Zakirkhodjaev, N., Husain, F. F., Lee-Smith, W., & Aziz, M. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07788-y · Cited by 26
Metadata
- Authors
- Castellsague, J., Riera-Guardia, N., Calingaert, B., Varas-Lorenzo, C., Fourrier-Reglat, A., Nicotra, F., Sturkenboom, M., Perez-Gutthann, S., & Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project
- Venue
- Drug Safety
- Published
- 2012-12
- Volume
- 35
- Issue
- 12
- Pages
- 1127-1146
- ISSN
- 0114-5916 (ISSN-L)
- 1179-1942
- OpenAlex
- W1984658180
- Cited by
- 341
- References
- 57
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.